27627
Pedro Marques da Silva, Carlos Aguiar
Bibliografia
1. Cones R, Rumana U. Current Treatment of Dyslipidemia:A New Paradigm for Statin Drug Use
and the Need for Additional Therapies. Drugs. 2015; 75: 1187-99.
2. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists’ (CTT) Collabo-
rators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of
data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-78.
3. Mihaylova B, Emberson J, Blackwell L, et al; Cholesterol Treatment Trialists’ (CTT) Colla-
borators. The effects of lowering LDL cholesterol with statin therapy in people at low risk
of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;
380: 581-90.
4. Baigent C, Blackwell L, Emberson J, et al, Cholesterol Treatment Trialists (CTT) Collabora-
tion Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data
from 170,000 participants in 26 randomised trials. Lancet. 2010; 376: 1670-81.
5. Brown MS, Faust JR, Goldstein JL, et al. Induction of 3-hydroxy-3-methylglutaryl coenzyme
A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive
inhibitor of the reductase. J Biol Chem. 1978; 253: 1121-8.
6. Satoh M, Takahashi Y, Tabuchi T, et al. Cellular and molecular mechanisms of statins: an
update on pleiotropic effects. Clin Sci (Lond). 2015; 129: 93-105.
7. Davignon J, Leiter LA. Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health
Risk Manag. 2005; 1: 29-40.
8. Robinson JG. Models for describing relations among the various statin drugs, low-density
lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. Am J Cardiol.
2008; 101: 1009-15.
9. Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014; 88: 3-11.
10. Elis A, Lishner M. Non-every day statin administration – a literature review. Eur J Intern Med.
2012; 23: 474-8.
11. Savarese G, Rosano GM, Parente A, et al. P. Reduction of C-reactive protein is not associated
with reduced cardiovascular risk and mortality in patients treated with statins. A meta-analy-
sis of 22 randomized trials. Int J Cardiol. 2014; 177: 152-60.
12. Bohula EA, Giugliano RP, Cannon CP, et al. . Achievement of Dual Low-Density Lipopro-
tein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the
Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT.
Circulation. 2015; 132: 1224-33.
13. Catapano AL, Reiner Z, De Backer G, et al. European Society of Cardiology (ESC); European
Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias
The Task Force for the management of dyslipidaemias of the European Society of Cardiology
(ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011; 217: 3-46.
14. Stone NJ, Robinson JG, Lichtenstein AH, et al. American College of Cardiology/American
Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treat-
ment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report
of the American College of Cardiology/American Heart Association Task Force on Practice
